Story perspectives

Novo Nordisk Launches Wegovy Subscription to Cut Costs

3/31/2026

Summary

Story summary

Novo Nordisk launched a Wegovy subscription program on March 31, 2026 to reduce self-pay costs.
The program offers three-, six-, and 12-month plans with lower prices for Wegovy injection and pill versions.
A 12-month subscription costs $249 per month and saves up to $1,200 annually on the injection and $600 on the pill.
The program aims to help patients manage costs and stay on treatment through Ro and WeightWatchers.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 established Medicare Part D, which began on January 1, 2006, providing prescription drug coverage to millions of seniors. By 2006, approximately 39 million beneficiaries were enrolled, addressing long-standing gaps in Medicare coverage. This initiative reflects ongoing efforts to enhance healthcare affordability, paralleling Novo Nordisk's Wegovy program aimed at reducing obesity treatment costs.

1 of 2

Story summary

Novo Nordisk launched a Wegovy subscription program on March 31, 2026 to reduce self-pay costs.
The program offers three-, six-, and 12-month plans with lower prices for Wegovy injection and pill versions.
A 12-month subscription costs $249 per month and saves up to $1,200 annually on the injection and $600 on the pill.
The program aims to help patients manage costs and stay on treatment through Ro and WeightWatchers.

1 / 2